Last checked at 28 Dec 2011 12:00
Tissue Regenix Group plc
("Tissue Regenix" or the "Company")
Result of General Meeting
Tissue Regenix Group plc (AIM: TRX), the regenerative medical device company, is pleased to announce that the resolutions proposed at the General Meeting held earlier today in connection with the placing of 181,818,182 new Ordinary Shares of 0.5p each (the "Placing")(the "Placing Shares") announced on 8 December 2011 were duly passed without amendment. Application has been made for admission of the Placing Shares to trade on AIM which is expected to take place on 29 December 2011.
Following the issue of the Placing Shares there will be 652,380,047 Ordinary Shares in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Tissue Regenix under the FSA's Disclosure and Transparency Rules.
Peel Hunt LLP is acting as nominated adviser and sole broker to the Company in connection with the Placing.
For further information:
Tissue Regenix Group plc | Tel: +44 (0)190 456 7609 |
Antony Odell, Managing Director Ian Jefferson, Chief Financial Officer | |
Peel Hunt LLP (Nominated Adviser and Broker) | Tel: +44 (0)20 7418 8900 |
James Steel Vijay Barathan Matthew Brooke-Hitching | |
FTI Consulting | Tel: +44 (0)20 831 3113 |
Ben Atwell John Dineen |